PAWS-GIST Research Projects

Research Initiatives

Since the start of PAWS-GIST in 2010 our aim has always been to stimulate research for improved treatments and a cure. It has taken a while as we needed first of all to set up The National GIST Tissue Bank, The PAWS-GIST clinic and then locate some researchers willing to work with us. However, our dream is beginning to come true...

Below is a list of  PAWS-GIST research, much of which has been funded by donations and grants made to PAWS-GIST that are held by GIST Cancer UK.

It is only as a result of fundraising by family friends and supporters that this work can happen.

Thanks to everyone who has and continues to raise funds for PAWS-GIST, look at what you are helping us to achieve!

Wildtype SDH Deficient GIST in the UK; A review of clinical course, genetics, epigenetics and metabolomics.

Dr Ruth Casey

Principal investigator (PI) - Dr Ruth Casey

Funding awarded by GCUK - £60,000

Project Duration - 3rd January 2017  to 31st December 2020.

Research outputs:

Dr Casey's research papers were published in PubMed as follows:

Next generation sequencing of WT GIST's to identify therapeutic targets.

Dr Newton Wong

Principal investigator (PI) - Dr Newton Wong

Funding awarded by GCUK - £15,389

Project Duration - 1st July 2017 - June 2020

Research outputs:

June 2020 - Dr Wong’s research paper “Next generation sequencing demonstrates the rarity of short kinase variants specific to quadruple wild type gastrointestinal stromal tumours”. Was published in the Journal of Clinical Pathology:  http://dx.doi.org/10.1136/jclinpath-2020-206613

Derivation, maintenance and characterisation of cell lines from biopsies of PAWS-GIST.

Dr Karen Sisley

Principal investigator (PI) - Dr Karen Sisley

Funding awarded by GCUK - £15,180

Project Duration - 1st August 2016 - ongoing

Research outputs: TBC

Research to investigate the potential of Gallium-68 (68Ga) DOTA-conjugated peptidePET/CT to develop theranostic applications in wild-type gastrointestinal stromal tumours (GISTs).

Dr Ruth Casey

Principal investigator (PI) - Dr Ruth Casey

Funding awarded by GCUK - £21,000

Project Duration - Starting in 2019

Research outputs: TBC

Investigating the utility of serum miRNA as a tumour biomarker to guide surveillance in patients with dSDH GIST and PPGL.

Dr Ruth Casey

Principal investigator (PI) - Dr Ruth Casey

Funding awarded by GCUK from the PAWS-GIST Research fund- £76,886

Project Duration -  2020 - December 2023

Research outputs: Preferential MGMT hypermethylation in SDH-deficient wild-type GIST

https://pubmed.ncbi.nlm.nih.gov/36198483/

 

Pilot Study - Altered RNA methylation in SDH deficient gastrointestinal stromal tumours

Dr Olivier Giger

Principal investigator (PI) - Dr Olivier Giger

Funding awarded by GCUK - £7,000

Project Duration - March 2019 - September 2019

Research outputs: Preferential MGMT hypermethylation in SDH-deficient wild-type GIST

https://pubmed.ncbi.nlm.nih.gov/36198483/

Metabolic alterations and vulnerabilities of succinate dehydrogenase-deficient GIST

Professor Eyal Gottlieb

Principal investigator (PI) - Professor Eyal Gottlieb

Funding awarded by GCUK - No Funding (Tissue supplied by National GIST Tissue Bank)

Project Duration - Commenced 2018

Research outputs: TBC

Investigating the potential of deuterium metabolic imaging in SDH-deficient GIST

Principal investigator (PI) - Dr Mary McLean

Funding awarded by GCUK - £20, 475

Project Duration - October 2023 - September 2025

Research outputs: TBC

Establishing novel models of SDH-deficient/Wild-type GIST for the testing of novel therapeutic strategies

Principal investigator (PI) - Professor Zoe Walters

Funding awarded for consumables on this project - £31, 463

Project Duration - November 2024 - November 2026

Research outputs: TBC

SDH-deficient GISTs affect approximately 60, predominantly younger individuals annually in the UK. They exhibit distinct biological characteristics compared to other GISTs with different mutations. One major limitation to finding new treatments is the lack of models of these cancers that can be used in the laboratory to identify and test new treatments. This project aims to develop new laboratory models of SDH-deficient GISTs to provide a platform to test new drugs for patients and pave the way for rapid translation into clinical trials.